BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28612375)

  • 1. Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report.
    Fernández KS; Schwartz CL; Chen L; Constine LS; Chauvenet A; de Alarcón PA
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28612375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
    Marks LJ; Pei Q; Bush R; Buxton A; Appel B; Kelly KM; Schwartz CL; Friedman DL
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27375. PubMed ID: 30277639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031.
    Parzuchowski A; Bush R; Pei Q; Friedman DL; FitzGerald TJ; Wolden SL; Dharmarajan KV; Constine LS; Laurie F; Kessel SK; Appel B; Fernandez K; Punnett A; Schwartz CL; Cox J; Terezakis SA
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1119-1125. PubMed ID: 29722656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.
    Schwartz CL; Chen L; McCarten K; Wolden S; Constine LS; Hutchison RE; de Alarcon PA; Keller FG; Kelly KM; Trippet TA; Voss SD; Friedman DL
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.
    Tebbi CK; Mendenhall NP; London WB; Williams JL; Hutchison RE; Fitzgerald TJ; de Alarcón PA; Schwartz C; Chauvenet A
    Pediatr Blood Cancer; 2012 Dec; 59(7):1259-65. PubMed ID: 22911615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.
    Schwartz CL; Constine LS; Villaluna D; London WB; Hutchison RE; Sposto R; Lipshultz SE; Turner CS; deAlarcon PA; Chauvenet A
    Blood; 2009 Sep; 114(10):2051-9. PubMed ID: 19584400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group.
    Kelly KM; Cole PD; Pei Q; Bush R; Roberts KB; Hodgson DC; McCarten KM; Cho SY; Schwartz C
    Br J Haematol; 2019 Oct; 187(1):39-48. PubMed ID: 31180135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
    Henderson TO; Parsons SK; Wroblewski KE; Chen L; Hong F; Smith SM; McNeer JL; Advani RH; Gascoyne RD; Constine LS; Horning S; Bartlett NL; Shah B; Connors JM; Leonard JI; Kahl BS; Kelly KM; Schwartz CL; Li H; Friedberg JW; Friedman DL; Gordon LI; Evens AM
    Cancer; 2018 Jan; 124(1):136-144. PubMed ID: 28902390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.
    Charpentier AM; Friedman DL; Wolden S; Schwartz C; Gill B; Sykes J; Albert-Green A; Kelly KM; Constine LS; Hodgson DC
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):943-950. PubMed ID: 27869096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
    Dörffel W; Rühl U; Lüders H; Claviez A; Albrecht M; Bökkerink J; Holte H; Karlen J; Mann G; Marciniak H; Niggli F; Schmiegelow K; Schwarze EW; Pötter R; Wickmann L; Schellong G
    J Clin Oncol; 2013 Apr; 31(12):1562-8. PubMed ID: 23509321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABVD or BEACOPP
    Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
    Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelines.
    Seror E; Donadieu J; Pacquement H; Abbou S; Lambilliotte A; Schell M; Curtillet C; Gandemer V; Pasquet M; Aladjidi N; Lutz P; Schmitt C; Deville A; Minckes O; Vanier JP; Armari-Alla C; Thomas C; Gorde-Grosjean S; Millot F; Blouin P; Garnier N; Coze C; Devoldere C; Reguerre Y; Helfre S; Claude L; Clavel J; Oberlin O; Landman-Parker J; Leblanc T
    Pediatr Hematol Oncol; 2016; 33(7-8):423-437. PubMed ID: 27960645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
    J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
    Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
    Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and outcomes in adolescents and young adults with Hodgkin lymphoma in pediatric versus adult centers: An IMPACT Cohort Study.
    Gupta S; Baxter NN; Hodgson D; Punnett A; Sutradhar R; Pole JD; Nagamuthu C; Lau C; Nathan PC
    Cancer Med; 2020 Oct; 9(19):6933-6945. PubMed ID: 32441450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group.
    Parikh RR; Kelly KM; Hodgson DC; Hoppe BS; McCarten KM; Karolczuk K; Pei Q; Wu Y; Cho SY; Schwartz C; Cole PD; Roberts K
    Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):890-900. PubMed ID: 34767937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study.
    Tebbi CK; Mendenhall N; London WB; Williams JL; de Alarcon PA; Chauvenet AR;
    Pediatr Blood Cancer; 2006 Feb; 46(2):198-202. PubMed ID: 16136581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.
    Appel BE; Chen L; Buxton AB; Hutchison RE; Hodgson DC; Ehrlich PF; Constine LS; Schwartz CL
    J Clin Oncol; 2016 Jul; 34(20):2372-9. PubMed ID: 27185849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.